1. Scrip
  2. >>Focus On Asia

The Glivec calculus: what changed after the hype

 
• By Anju Ghangurde

Hyperbolists think that the decision of the Indian Supreme Court to reject Novartis' Glivec (imatinib mesylate) patent claim has changed the face of the pharma market in India and perhaps in other emerging pharma nations, too. But calmer calculus makes it clear that everything is not quite that dramatic. Sure, India and other BRIC nations are not going to align their intellectual property fully with the West. But that does not mean that incremental innovation is fruitless, or that emerging markets are solely price-driven, or that multinationals will rethink investment in emerging nations. Scrip looks beyond the hyperbole at some of the key messages from the landmark verdict.

Hyperbolists think that the decision of the Indian Supreme Court to reject Novartis' Glivec (imatinib mesylate) patent claim has changed the face of the pharma market in India and perhaps in other emerging pharma nations, too. But calmer calculus makes it clear that everything is not quite that dramatic. Sure, India and other BRIC nations are not going to align their intellectual property fully with the West. But that does not mean that incremental innovation is fruitless, or that emerging markets are solely price-driven, or that multinationals will rethink investment in emerging nations. Scrip looks beyond the hyperbole at some of the key messages from the landmark verdict.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Focus On Asia

Asia Deal Watch: Daiichi Taps Into Wayfinder’s RNA-Encoding Platform

 
• By Jung Won Shin, Lisa Takagi, Joseph Haas, Anju Ghangurde, and Vibha Ravi

Plus deals involving Elix/PRISM, Rege/Syros, Kaken/KalVista, Dr. Reddy’s/Aurigene/Edity, Nissan Chemical/Sanwa, Lupin/Renascience, Shionogi/Link Medicine, Abbisko/Merck & Co., Ono/Reborna and Apollomics/LaunXp.

Japan’s Ciconia Seeks Academic Candidates To Hatch In Global Market

 
• By Lisa Takagi

Japanese incubator Ciconia has just started verifying its first drug candidate with a vision of building domestic startups with globally competitive assets.

Henlius In David Versus Goliath Race With Pfizer For First PD-L1 ADC

 
• By Dexter Jie Yan

While Henlius Biotech’s PD-L1-targeting antibody-drug conjugate HLX43 is struggling to catch up with Pfizer’s PF-08046054, the global frontrunner in the space, a key differentiation of the China-originated asset could lie in PD-L1-negative patients.

US-China Tariff War Pressures Pharma’s Complex Supply Chain

 
• By Lisa Takagi

Although pharmaceuticals are exempt from the US reciprocal tariff policy, for now, the escalating global trade war is already posing practical on-the-ground problems for some companies, Scrip hears.

More from Scrip

Seven Up For Sanofi and Regeneron With Dupixent CSU Approval

 
• By Kevin Grogan

The IL-4/IL-13 inhibitor has been approved in the US as the first targeted therapy in over a decade for chronic itching.

Japan’s Ciconia Seeks Academic Candidates To Hatch In Global Market

 
• By Lisa Takagi

Japanese incubator Ciconia has just started verifying its first drug candidate with a vision of building domestic startups with globally competitive assets.

Sanofi Licenses Bispecific Candidates From AI-Driven Earendil

 
• By Joseph Haas

Deal Snapshot: Sanofi obtained global rights to a pair of bispecific antibody candidates for autoimmune and inflammatory bowel disorders from Helixon-affiliated AI firm Earendil.